Biopharma buyouts bounce back
Developers brush off antitrust scrutiny and drug price curbs and succumb to the urge to merge.
UCB leads the stale scale
Several big groups’ portfolios are ageing, and regulatory action risks blocking their renewal.
Spotlight – Few signs of gout pipeline flaring up
Asian developers dominate biopharma’s gout pipeline, with Selecta and Sobi’s SEL-212 standing out as a rare globally focused project.
Mulling biopharma’s Minority Report moment
Amgen might yet prevail in its attempt to buy Horizon, but the FTC shockwaves will still be felt.
Heightened US antitrust fears rattle biopharma
The FTC moves to block Amgen’s Horizon takeout, broadening its remit to curb anticompetitive moves that inflate drug prices.
A blockbuster year could be building
If forecasts prove accurate 2023 could be the biggest year for blockbuster launches for some time.
Viridian aims to prove itself in thyroid eye
Forthcoming data will see the group take on Horizon, but subcutaneous projects could pose the real threat.